Premium
Elevation of sialyl stage‐specific mouse embryonic antigen levels in pleural effusion in patients with adenocarcinoma of the lung
Author(s) -
Iguchi Haruo,
Hara Nobuyuki,
Miyazaki Kazuhiro,
Ohtsu Yasuhiro,
Sonoda Fumitaka,
Ohta Mitsuo
Publication year - 1989
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19890401)63:7<1327::aid-cncr2820630717>3.0.co;2-q
Subject(s) - medicine , carcinoembryonic antigen , adenocarcinoma , pleural effusion , pathology , lung , respiratory disease , lung cancer , gastroenterology , cancer
Abstract Sialyl stage‐specific mouse embryonic antigen (SSEA‐1) levels were measured in pleural effusions obtained from patients with lung cancer and benign pulmonary disease, using a solid‐phase immunoradiometric sandwich assay. The mean ( ± nSEM) levels (unit/ml) of pleural fluid sialyl SSEA‐1 were 3620 ± n 1419 in adenocarcinoma (n = 25), 123 ± n 30 in nonadenocarcinoma (n = 13) and 95 ± n 19 in benign pulmonary disease (n = 13), respectively. The positive rate was 64% in adenocarcinoma, 7.7% in nonadenocarcinoma, and 0% in benign pulmonary disease, respectively, when a cutoff level was defined as the mean + 3 SD value (300 unit/ml) based on pleural fluid sialyl SSEA‐1 levels in benign pulmonary disease. There was a significant positive correlation between pleural fluid levels of sialyl SSEA‐1 and those of carcinoembryonic antigen in adenocarcinoma patients ( r = 0.8246, P < 0.01). Pleural fluid sialyl SSEA‐1 levels correlated with cytologic findings in adenocarcinoma patients. These observations suggest that sialyl SSEA‐1 in pleural effusion is a useful marker to discriminate malignant from nonmalignant and adenocarcinoma from nonadenocarcinoma of the lung.